In Corporate Livewire‘s June 2013 Round Table “Biotech & Pharmaceutical,” Dr. Gregory Bell and other leading experts discuss changes and analyze the effects they will have in the industry.
Evidence requirements for orphan drugs
CRA’s Life Sciences Practice focuses on global policy, commercialization, and market access issues dedicated to orphan drug issues, including orphan evidence...